Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
WEBFeb 16, 2023 · In a phase 2 study, rucaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had metastatic, castration-resistant prostate cancer associated...
Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy …
WEBMay 15, 2020 · BOULDER, Colo.–(BUSINESS WIRE)– Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca ® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who ...
FDA grants accelerated approval to rucaparib for BRCA-mutated ...
WEBOn May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or...
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer
WEBJun 11, 2020 · UPDATE: According to results from a large clinical trial called TRITON3, treatment with rucaparib (Rubraca) improves how long some people with metastatic prostate cancer live without their cancer getting worse.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy …
WEBJun 6, 2022 · In ATHENA–MONO, rucaparib maintenance treatment significantly improved PFS versus placebo for patients with newly diagnosed advanced ovarian cancer regardless of BRCA or HRD status.
Rucaparib plus enzalutamide in patients (pts) with metastatic ...
WEBMar 2, 2021 · The potential for drug-drug interaction between rucaparib and enzalutamide was recognized as enzalutamide is a strong clinical inducer of CYP3A4, a mediator of the formation of rucaparib metabolite M324.
Rucaparib efficacious in metastatic castration-resistant prostate …
WEBFeb 17, 2023 · For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared...
BREAKING NEWS: FDA Approves Rucaparib For Treatment of …
WEBMay 15, 2020 · Today we are thrilled to announce that the U.S. Food and Drug Administration (FDA) approved rucaparib, a new medication to treat some patients with advanced prostate cancer. PCF science is proud to have been involved since the beginning, in every stage of the research that lead to this development.
Efficacy and safety of rucaparib treatment in patients with BRCA ...
WEBDec 8, 2022 · Here we report the final efficacy and safety results in heavily pretreated patients with ovarian cancer who received rucaparib in Study 10 Parts 2A and 2B.
Rucaparib versus standard-of-care chemotherapy in patients with ...
WEBMar 14, 2022 · The results of this trial show that rucaparib significantly improved progression-free survival versus the active comparator of chemotherapy in a population of patients with relapsed, heavily pretreated, BRCA1-mutated or BRCA2-mutated ovarian cancer, including those with platinum-resistant, partially platinum-sensitive, and …